Oct. 3 at 9:48 PM
$TIVC Looking for opinions on a topic I just discovered. Due diligence on the COO, Michael Handley, reveals that he was the CEO of Statera from 2020 until February of this year when he joined Tivic.
This means he was the one that agreed to sell Entolimod at such a low price to Tivic and then followed the asset two weeks later. Was this widely known and discussed when the announcement hit?
This seems bearish at first glance because he had the asset for 5 years and failed to advance it. What makes him the right person now?
My other thought was that the timing with Covid and a major downturn in biotech, coupled with merger issues doomed Statera. He believed so strongly in Entolimod that he joined Tivic to see it through and is absolutely the right man for the job.
Has anyone else looked at this and developed an informed opinion?
